---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-048971"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2026-04-27T23:59:59+00:00"
generated_at: "2026-05-15T03:45:49.834834+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sagimet pivots to acne, pauses MASH; cash $104.5M; Phase 3 acne trial H2 2026

## Summary
- Preliminary cash balance $104.5M as of Mar 31, 2026; provides runway for strategic pivot.
- Phase 3 U.S. trial of denifanstat in moderate-to-severe acne planned for H2 2026, pending IND clearance.
- MASH development paused until non-dilutive funding secured; combination program with resmetirom ready for Phase 2.
- New CMO Andreas Grauer appointed; Phase 1 of TVB-3567 ongoing, Phase 2 acne trial targeted for H2 2026.
- Positive Phase 3 acne safety results from partner Ascletis in China reported Jan 2026 (n=240).

## SEC filing metadata
- accession: 0001104659-26-048971
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2026-04-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465926048971/0001104659-26-048971-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465926048971/tm2612738d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-048971
- JSON: https://secwatch.observer/filing/0001104659-26-048971.json
- Plain text: https://secwatch.observer/filing/0001104659-26-048971.txt

## Key facts
- Earnings Releases
  Sagimet Biosciences Inc. reported preliminary financial results for the Company’s fiscal quarter ended March 31, 2026.
  - Period: the Company’s fiscal quarter ended March 31, 2026
  - Result: preliminary results
  source text: Sagimet Biosciences, Inc. (the “ Company ”) is furnishing with this Current Report on Form 8-K (the “Current Report”) certain unaudited preliminary financial information for the Company’s fiscal quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1400118/000110465926048971/0001104659-26-048971-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.